NAD Precursors Class Overview Monograph

Biochemical Rationale and Mechanism of Action

NAD+ is a redox coenzyme that shuttles electrons in glycolysis, the TCA cycle, and oxidative phosphorylation. It also serves as a consumed substrate for sirtuins (SIRT1 through SIRT7), poly-ADP-ribose polymerases (PARPs), and CD38/CD157 ectoenzymes. Each of these consumer reactions cleaves NAD+ and releases nicotinamide, which must be recycled back to NAD+ through the salvage pathway [1].

Why NAD+ Declines With Age

Tissue NAD+ concentrations fall by an estimated 50% between age 40 and 60 in human skin biopsies and by comparable margins in rodent liver, brain, and skeletal muscle [2]. The decline is driven primarily by rising CD38 expression in senescent and inflammatory cells, increased PARP activation from accumulated DNA damage, and reduced expression of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting salvage enzyme [3].

Biosynthesis Pathways

Mammals synthesize NAD+ through three routes. The de novo pathway converts dietary tryptophan via the kynurenine cascade. The Preiss-Handler pathway converts niacin (nicotinic acid) to NAD+ through nicotinic acid mononucleotide. The salvage pathway recycles nicotinamide to NMN via NAMPT, then NMN to NAD+ via NMNAT enzymes. NR enters the salvage pathway after phosphorylation by NR kinases (NRK1/NRK2), bypassing the NAMPT bottleneck entirely [1].

This bypass is the pharmacologic rationale for NR and NMN. Both feed into the pathway downstream of the rate-limiting step.

Sirtuin and PARP Activation

Higher NAD+ availability increases sirtuin deacetylase activity, which regulates mitochondrial biogenesis (SIRT1/SIRT3), DNA repair (SIRT6), and inflammatory signaling (SIRT1-mediated NF-kB deacetylation). PARP1, the primary DNA repair enzyme, consumes roughly 80% of cellular NAD+ under genotoxic stress. The therapeutic hypothesis is straightforward: replenishing NAD+ restores the balance between repair capacity and metabolic signaling [2].

Agents in the Class

Nicotinamide Riboside (NR)

NR is a pyridine nucleoside form of vitamin B3. ChromaDex markets it as Niagen and holds key composition-of-matter patents. The FDA granted NR new dietary ingredient (NDI) status in 2013, and it received GRAS determination in 2016. NR is phosphorylated intracellularly by NRK1 and NRK2 to form NMN, then converted to NAD+ by NMNAT enzymes [4].

Oral bioavailability is moderate. A single 1,000 mg dose in eight healthy volunteers raised whole-blood NAD+ 2.7-fold at peak (8 hours), with a return toward baseline by 24 hours [5]. Repeated dosing at 1,000 mg/day for 6 weeks in the Martens et al. Crossover trial (N=24, healthy adults aged 55 to 79) produced a sustained 60% increase in NAD+ levels over placebo [6].

Nicotinamide Mononucleotide (NMN)

NMN is a nucleotide intermediate one step closer to NAD+ than NR. It was widely sold as a supplement until November 2022, when the FDA argued that NMN could not be marketed as a dietary supplement because Metro International Biotech had previously filed an investigational new drug (IND) application for it. That ruling remains contested. NMN is still available through multiple manufacturers, though its legal classification differs by jurisdiction [7].

Oral NMN at 250 mg/day for 10 weeks raised blood NAD+ by 38% in overweight, prediabetic postmenopausal women (N=25) in the Yoshino et al. Trial. That same trial showed improved skeletal muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp [8].

Niacin (Nicotinic Acid)

Niacin is the oldest NAD+ precursor in clinical use and the only one with proven cardiovascular endpoint data from the pre-statin era. The Coronary Drug Project (N=8,341, 1975) showed a 26% reduction in nonfatal MI with niacin 3 g/day over 6 years [9]. Extended-release niacin (Niaspan) was FDA-approved for dyslipidemia and remains a prescription option, though its use declined sharply after AIM-HIGH (N=3,414) and HPS2-THRIVE (N=25,673) showed no incremental cardiovascular benefit when added to statin therapy [10].

Niacin's dose-limiting side effect is prostaglandin D2-mediated cutaneous flushing. Extended-release formulations and co-administration with laropiprant reduce flushing but do not eliminate it.

Nicotinamide (Niacinamide)

Nicotinamide is the amide form of niacin. It does not cause flushing and raises NAD+ through direct entry into the salvage pathway. The ONTRAC trial (N=386) demonstrated that nicotinamide 500 mg twice daily reduced the rate of new nonmelanoma skin cancers by 23% over 12 months compared to placebo in high-risk patients [11]. Nicotinamide is inexpensive and widely available OTC.

A significant pharmacologic limitation exists: at high doses (above 1 to 3 g/day), nicotinamide inhibits sirtuins through product inhibition, potentially negating the intended benefit of raising NAD+ [1].

Pharmacokinetics

All oral NAD+ precursors undergo extensive first-pass hepatic metabolism. NR and NMN are partially degraded to nicotinamide in the gut and liver before reaching systemic circulation. Trammell et al. Showed that a single 1,000 mg oral dose of NR produced measurable increases in plasma NR, NAM, and NAAD within 1 hour, with peak NAD+ elevation at 8 hours [5].

Tissue Distribution

Rodent data indicate that orally administered NMN raises NAD+ in liver, skeletal muscle, adipose tissue, and hypothalamus within 15 minutes of intraperitoneal injection. Oral dosing in humans shows strong blood NAD+ increases, but direct tissue NAD+ measurements in human trials are limited to skeletal muscle biopsies from two small studies [8][12].

Metabolism and Elimination

NR and NMN are converted to NAD+ and then follow normal NAD+ turnover. The primary urinary metabolites are N-methyl-2-pyridone-5-carboxamide (2-PY) and N-methyl-nicotinamide (MeNAM). Niacin is additionally metabolized through conjugation to nicotinuric acid. No dose adjustment data exist for hepatic or renal impairment for NR or NMN specifically, though niacin carries labeling for hepatotoxicity risk at high doses.

Clinical Trial Evidence

NR Trials

The Martens et al. 2018 crossover trial (N=24) remains the most-cited NR study in older adults. NR 1,000 mg/day for 6 weeks was well tolerated and reduced systolic blood pressure by 6 mmHg in the subgroup with stage 1 hypertension, though this was a secondary endpoint [6]. Elhassan et al. (N=12, men aged 70 to 80) confirmed that NR 1,000 mg/day for 21 days increased skeletal muscle NAD+ metabolome concentrations and reduced circulating inflammatory cytokines [12].

Conze et al. Conducted the largest NR safety study to date (N=140, 8 weeks, doses up to 1,000 mg/day), finding no significant differences in adverse events between NR and placebo groups. Hepatic transaminases, creatinine, and complete blood counts remained within normal limits [13].

NMN Trials

Yoshino et al. 2021 (N=25, postmenopausal women with prediabetes) showed that NMN 250 mg/day for 10 weeks increased muscle insulin signaling and improved insulin-stimulated glucose disposal by approximately 25% on clamp studies, without significant changes in body weight or HbA1c [8].

A 2022 randomized trial by Yi et al. (N=66, healthy middle-aged adults) reported that NMN 600 mg and 1,200 mg/day for 60 days raised blood NAD+ in a dose-dependent manner and improved 6-minute walk distance compared to placebo [14].

Niacin Outcome Trials

As noted, niacin's cardiovascular endpoint data come from the pre-statin era. Dr. William Cefalu, then at the Pennington Biomedical Research Center, stated in a 2014 review: "Niacin remains the most effective available agent for raising HDL cholesterol, but the failure of AIM-HIGH and HPS2-THRIVE to show benefit on top of statins has fundamentally changed its clinical positioning" [10].

The Endocrine Society's 2023 lipid management guidelines recommend against routine addition of niacin to statin therapy for cardiovascular risk reduction, citing the lack of incremental benefit and the hepatotoxicity and glycemic risks at high doses [15].

Dosing and Administration

NR Dosing

Most published trials use 250 to 1,000 mg/day, given as a single morning dose or split twice daily. The 1,000 mg/day dose provides the most consistent NAD+ elevation in published data. NR is taken orally with or without food. No titration protocol exists in the literature.

NMN Dosing

Clinical trial doses range from 250 to 1,200 mg/day. The 250 mg/day dose used in Yoshino et al. Represents the minimum effective dose demonstrated for a metabolic endpoint. Sublingual and enteric-coated formulations are marketed but lack comparative bioavailability data against standard oral capsules.

Niacin Dosing

Extended-release niacin (Niaspan) is initiated at 500 mg at bedtime and titrated by 500 mg every 4 weeks to a target of 1,000 to 2,000 mg/day. Taking the dose at bedtime with a low-fat snack and pretreatment with aspirin 325 mg reduces flushing.

Immediate-release niacin carries higher hepatotoxicity risk at equivalent doses and should be avoided when extended-release is available.

Adverse Effects and Safety

NR and NMN

Short-term safety profiles are reassuring. Across published trials (total N exceeding 300 for NR, approximately 150 for NMN), the most common reported effects are mild GI symptoms: nausea, bloating, and diarrhea. No serious adverse events have been attributed to NR or NMN in controlled studies up to 12 weeks [13][14].

Theoretical concerns exist. NAD+ fuels PARP activity and sirtuin-mediated DNA repair in healthy cells, but could theoretically support the same processes in malignant cells. No human cancer signal has emerged in published trials, though preclinical data are mixed. Clinicians should exercise caution in patients with active malignancy until longer-term data are available.

Niacin

Niacin carries a well-characterized adverse effect profile: flushing (up to 70% incidence at therapeutic doses), hepatotoxicity (particularly with sustained-release formulations), hyperuricemia, and worsening of insulin resistance at doses above 1.5 g/day. Niacin-induced hepatitis is rare but can be severe, especially if patients switch between immediate-release and sustained-release formulations without dose adjustment [10].

Nicotinamide

Generally well tolerated up to 1,500 mg/day. GI upset and headache are the primary complaints. The ONTRAC trial reported no significant safety signals at 1,000 mg/day for 12 months [11].

Monitoring Recommendations

No consensus monitoring guidelines exist for NR or NMN. Based on available safety data and mechanistic considerations, the following baseline and follow-up panel is reasonable for prescribers:

Baseline (before initiation): hepatic transaminases (ALT, AST), uric acid, fasting glucose or HbA1c, fasting lipid panel, CBC with differential. For niacin specifically, add LDH and total bilirubin.

Follow-up at 8 to 12 weeks: repeat hepatic transaminases, uric acid, and fasting glucose. For niacin, repeat full lipid panel. For NR/NMN used in metabolic contexts, consider repeating fasting insulin or HOMA-IR if baseline values were abnormal.

Dr. Charles Brenner, discoverer of the NR kinase pathway, has stated: "Whole-blood NAD+ measurement is the most reliable pharmacodynamic biomarker for NR supplementation, but it is not yet standardized across clinical laboratories" [4].

Drug Interactions

Niacin-Specific Interactions

Niacin combined with statins increases myopathy risk, particularly with lovastatin and simvastatin. The HPS2-THRIVE trial (N=25,673) demonstrated excess myopathy and rhabdomyolysis when niacin-laropiprant was added to simvastatin [10]. Niacin also potentiates the hypotensive effects of antihypertensives and can worsen glycemic control in patients on insulin or sulfonylureas.

Class-Wide Considerations

All NAD+ precursors generate nicotinamide as a metabolic byproduct, which is methylated by NNMT (nicotinamide N-methyltransferase) using S-adenosylmethionine (SAM) as a methyl donor. High-dose NAD+ precursor use may increase methyl group demand. Whether this is clinically significant in patients with adequate folate and B12 status is unknown, but monitoring homocysteine in patients on high-dose regimens (above 1 g/day of NR or NMN) is a reasonable precaution.

No pharmacokinetic interaction studies have been published for NR or NMN with common co-prescribed medications including metformin, rapamycin, or resveratrol, despite frequent co-use in longevity protocols.

Prescribing Considerations for Clinicians

NR and NMN are not FDA-approved drugs. Prescribers who recommend them are operating in a supplement or compounding context. Clinicians should document the rationale (typically age-related NAD+ decline with metabolic or neurodegenerative risk factors), obtain informed consent noting the absence of long-term outcome data, and establish a monitoring plan.

Patient Selection

Candidates most likely to derive measurable benefit based on current evidence include adults over 55 with evidence of metabolic dysfunction (prediabetes, insulin resistance) or those with documented NAD+ depletion on specialized testing. The evidence base does not support recommending NAD+ precursors to healthy young adults.

Formulation Quality

Because NR and NMN are marketed as supplements, potency and purity vary across manufacturers. Third-party certification (NSF International, USP Verified) provides the most reliable quality assurance. Clinicians should specify tested brands or pharmacy-compounded formulations when recommending these agents.

Whole-blood NAD+ can be measured by specialty labs using liquid chromatography-mass spectrometry, with a typical reference range of 20 to 45 mcM in adults over 50. A follow-up measurement at 6 to 8 weeks after initiation can confirm pharmacodynamic response and guide dose adjustment.